{"hq_id":"hq-c-org-000204","name":"Psilocybin","context":"human_adult","timestamp":"2026-10-27T20:20:01.972Z","derived_by":{"label":"ALETHEIA-derived","engine":{"commit":"a1c6e861599cc34c5db0318ea1a7ac13a327e074","commit_source":"vercel_env","tree_clean":null},"params":{"sha256":"88ae43137e58ed0cd65588409efefee0d90253da01ef4459bf9ee25f888ec9a0","files":["axes.json","context-specificity.json","regulatory-mappings.json","synthesis-params.json","thresholds.json"]},"clock":{"year":2026},"inputs":[{"id":"hq-c-org-000204","sha256":"89e262b8220d2e6fc116f219817ca59bf01b307eae10c3d2d2bd0e9733e49272"}]},"risk_level":"moderate","risk_profile":{"magnitude":{"mean":0.3,"weightedMean":0.3,"std_dev":0,"confidence_interval_95":[0.3,0.3],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.3,"weight":0.35}]},"confidence":{"mean":0.5,"weightedMean":0.5,"std_dev":0,"confidence_interval_95":[0.5,0.5],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.5,"weight":0.35}]},"recency":{"mean":1,"weightedMean":1,"std_dev":0,"confidence_interval_95":[1,1],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":1,"weight":0.35}]},"methodology":{"mean":0.7,"weightedMean":0.7,"std_dev":0,"confidence_interval_95":[0.7,0.7],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.7,"weight":0.35}]},"specificity":{"mean":0.92,"weightedMean":0.92,"std_dev":0,"confidence_interval_95":[0.92,0.92],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.92,"weight":0.35}]},"consensus":{"exists":false,"strength":0,"disagreement_magnitude":0,"warning":"single_source_warning"}},"interpretation":{"summary":"Single source (HQ_DIRECT, 2026) indicates moderate risk.","confidence_note":"Evidence quality varies; interpretation requires caution.","context_note":null,"warning":"single_source_warning"},"sources":[{"id":"dea_psilocybin_schedule_i","type":"regulatory","title":"US DEA: Psilocybin and Psilocin — Schedule I Classification, FDA Breakthrough Therapy Designations (Depression), Oregon and Colorado Regulatory Frameworks, Australia Therapeutic Authorization (2023), and Mushroom Misidentification with Galerina (2023)","year":2023},{"id":"carhart_harris_psilocybin_review","type":"academic","title":"Carhart-Harris R, Goodwin GM: The Therapeutic Potential of Psychedelic Drugs — Psilocybin 5-HT2A Mechanism, Clinical Trial Efficacy Data (TRD and MDD), Physiological Safety Profile, Risk-Benefit at Therapeutic Doses, and Adolescent Brain Development Considerations (Neuropsychopharmacology, 2017; updated 2023)","year":2023},{"id":"r60-2026-09-30-d918-oehha-prop65-list-csv-own-url","type":"regulatory","title":"OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26)","url":"https://oehha.ca.gov/sites/default/files/media/2025-01/p65chemicalslist.csv"},{"id":"r60-2026-10-02-d-955-s9-d955-s9-osha-table-z-1","type":"regulatory","title":"Permissible Exposure Limits – OSHA Annotated Table Z-1","url":"https://www.osha.gov/annotated-pels/table-z-1"},{"id":"ctx_pred_dtxsid0048898","type":"reference","title":"EPA CompTox CTX API: predicted properties for DTXSID0048898 (Psilocybin)","url":"https://comptox.epa.gov/ctx-api/chemical/property/predicted/search/by-dtxsid/DTXSID0048898"}],"sources_scope":"context","derived_markers":[],"warnings":["unmapped_classification:DEA:schedule i","unmapped_classification:FDA:breakthrough therapy designation","single_source_warning"],"meta":{"synthesis_version":"1.1.0","config_version":"1.1.0","n_sources":1,"db_version":45,"warnings":["unmapped_classification:DEA:schedule i","unmapped_classification:FDA:breakthrough therapy designation"]},"schema":"synthesis","_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer","available_contexts":["human_adult","human_child","exposure_ingestion","human_teen","human_elderly","human_infant","human_pregnant"],"unsourced_values":["safety.dose_response.ld50"]}